Abstract
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. Secondary objectives included response evaluation and safety. A planned interim analysis occurred after 189 events. Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in the placebo arm). In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm (P = .004). In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%). Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3638-3646 |
| Number of pages | 9 |
| Journal | Journal of Clinical Oncology |
| Volume | 35 |
| Issue number | 32 |
| DOIs | |
| State | Published - Nov 10 2017 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
MONARCH 3 : Abemaciclib as initial therapy for advanced breast cancer. / Goetz, Matthew Philip; Toi, Masakazu; Campone, Mario; Trédan, Olivier; Bourayou, Nawel; Sohn, Joohyuk; Park, In Hae; Paluch-Shimon, Shani; Huober, Jens; Chen, Shin Cheh; Manso, Luis; Barriga, Susana; Freedman, Orit C.; Jaliffe, Georgina Garnica; Forrester, Tammy; Frenzel, Martin; Smith, Ian C.; Di Leo, Angelo.
In: Journal of Clinical Oncology, Vol. 35, No. 32, 10.11.2017, p. 3638-3646.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - MONARCH 3
T2 - Abemaciclib as initial therapy for advanced breast cancer
AU - Goetz, Matthew Philip
AU - Toi, Masakazu
AU - Campone, Mario
AU - Trédan, Olivier
AU - Bourayou, Nawel
AU - Sohn, Joohyuk
AU - Park, In Hae
AU - Paluch-Shimon, Shani
AU - Huober, Jens
AU - Chen, Shin Cheh
AU - Manso, Luis
AU - Barriga, Susana
AU - Freedman, Orit C.
AU - Jaliffe, Georgina Garnica
AU - Forrester, Tammy
AU - Frenzel, Martin
AU - Smith, Ian C.
AU - Di Leo, Angelo
PY - 2017/11/10
Y1 - 2017/11/10
N2 - Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. Secondary objectives included response evaluation and safety. A planned interim analysis occurred after 189 events. Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in the placebo arm). In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm (P = .004). In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%). Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
AB - Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. Secondary objectives included response evaluation and safety. A planned interim analysis occurred after 189 events. Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in the placebo arm). In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm (P = .004). In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%). Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85032984371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032984371&partnerID=8YFLogxK
U2 - 10.1200/JCO.2017.75.6155
DO - 10.1200/JCO.2017.75.6155
M3 - Article
C2 - 28968163
AN - SCOPUS:85032984371
VL - 35
SP - 3638
EP - 3646
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 32
ER -